Lakefront Biotherapeutics (LKFT) Gross Profit (2021 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Gross Profit for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

• Quarterly Gross Profit fell 97.25% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 432.25% YoY) and the FY2025 annual result came in at $1.2 billion, up 349.57% from the prior year.
• Gross Profit fell to $1.9 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
• Over the last five years, Gross Profit for LKFT reached as high as $1.0 billion in Q4 2025 and fell as low as -$57.6 million in Q2 2024.
• A 5-year average of $118.1 million and a median of $63.5 million in 2023 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2024 — Gross Profit sank 190.74% — and 2025, when it surged 9087.42%.
• Year by year, Gross Profit stood at $201.0 million in 2022, then tumbled by 46.61% to $107.3 million in 2023, then sank by 89.61% to $11.2 million in 2024, then jumped by 9087.42% to $1.0 billion in 2025, then plunged by 99.81% to $1.9 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $1.9 million, $1.0 billion, and $68.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.